A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma

European Journal of Cancer

Volumn 48, Issue 4, 2012, Pages 564-570

  Duffaud, Florence ^a   Egerer, Gerlinde ^b   Ferrari, Stefano ^c   Rassam, Hisham ^d   Boecker, Ulrike ^e   Bui Nguyen, B ^f  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d ELI LILLY AND COMPANY   (United States)

^e LILLY DEUTSCHLAND GMBH   (Germany)

^f INSTITUT BERGONIÉ   (France)

Author keywords

Clinical trial; Osteosarcoma; Pemetrexed; Phase II; Relapse; Response; Second line

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; METHOTREXATE; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW APLASIA; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RATING SCALE; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOSARCOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857062135     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.12.015     Document Type: Conference Paper

References (19)

1. P.C. Hogendoorn, ESMO/EUROBONET Working Group, and N. Athanasou Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v204 v213
2. C.M. Hattinger, M. Pasello, S. Ferrari, P. Picci, and M. Serra Emerging drugs for high-grade osteosarcoma Exp Opin Emerg Drugs 15 2010 615 634
3. N.C. Daw, C.A. Billups, and C. Rodriguez-Galindo Metastatic osteosarcoma Cancer 106 2006 403 412
4. N.J. Vogelzang, J.J. Rusthoven, and J. Symanowski Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644 (Pubitemid 46606305)
5. N. Hanna, F.A. Shepherd, and F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597 (Pubitemid 41079796)
6. T. Ciuleanu, T. Brodowicz, and C. Zielinski Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
7. G.V. Scagliotti, P. Parikh, and J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
8. G.B. Grindey, C. Shih, and C.J. Barnett LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS) Proc Am Assoc Cancer Res 33 1992 411 [abstr 2451]
9. C. Shih, G.B. Grindey, and C.J. Barnett Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514 Proc Am Assoc Cancer Res. 33 1992 411 [abstr 2452]
10. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
11. ALIMTA (pemetrexed for injection) [package insert]. Indianapolis, IN: Eli Lilly and Company; July 2009.
12. L.M. Leemis, and K.S. Trivedi A comparison of approximate interval estimators for the Bernoulli parameter Am Stat 50 1996 63 68
13. The International Agency for Research on Cancer (IARC), C.D.M. Fletcher, K. Krishnan Unni, and F. Mertens Pathology and genetics of tumours of soft tissue and bone (IARC WHO Classification of Tumours) 2006 IARC Press Lyon, France 270
14. D.J. Wagener, A.T. van Oosterom, and J.H. Mulder Phase II study of low-dose methotrexate in advanced osteosarcoma followed by escalation after disease progression: a study of the soft tissue and bone sarcoma group of the European Organization for Research on Treatment Cancer Cancer Treat Rep 70 1986 615 618 (Pubitemid 16121009)
15. K. O'Day, and R. Gorlick Novel therapeutic agents for osteosarcoma Expert Rev Anticancer Ther 9 2009 511 523
16. M.B. Harris, A.B. Cantor, and A.M. Goorin Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study Med Pediatr Oncol 24 1995 87 92
17. F. Fagioli, M. Aglietta, and A. Tienghi High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study J Clin Oncol 20 2002 2150 2156 (Pubitemid 34408807)
18. S. Ferrari, A. Briccoli, and M. Mercuri Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival J Clin Oncol 21 2003 710 715 (Pubitemid 46621907)
19. B. Kempf-Bielack, S.S. Bielack, and H. Jürgens Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS) J Clin Oncol 23 2005 559 568 (Pubitemid 46224233)